argenx Presents New Efgartigimod Data Showing Long-Term Sustained Patient Benefit in Myositis and Sjogren's Disease at EULAR 2026
StockNews.AI · 2 hours
AI Summary
argenx reports new EULAR data for efgartigimod across myositis and Sjögren's disease, showing durable TIS gains and a steady safety profile. Results from ALKIVIA+ and RHO+ suggest sustained responses and favorable dosing flexibility. Phase 3 ALKIVIA topline due 3Q2026 and UNITY topline 2H2027 could support broader FcRn-driven indications.
Sentiment Rationale
Positive interim and open-label data improve confidence in efgartigimod's long-term disease-modifying potential and dosing flexibility; upcoming Phase 3 topline (Q3 2026) and UNITY readouts (H2 2027) are near-term catalysts that could lift valuation if results remain favorable.
Trading Thesis
Near-term catalysts from EULAR data and 3Q2026 ALKIVIA topline could drive upside on ARGX if safety and efficacy trends persist.
Market-Moving
- ALKIVIA Phase 3 topline timing could spark a price move.
- Biweekly dosing safety in Sjögren's supports SC formulation potential.
- Cross-indication safety data may de-risk FcRn strategy.
- ENHANZE SC delivery by Halozyme could boost patient access.
Key Facts
- ARGX presents efgartigimod data at EULAR across myositis and Sjögren's.
- ALKIVIA+ Week 52: 37.5% major TIS maintained; 33.3% switched from placebo.
- RHO+: biweekly dosing maintains response in Sjögren's patients.
- Phase 3 ALKIVIA topline due 3Q2026; UNITY results expected 2H2027.
- Cross-indication safety: 834 patients, >1,300 patient-years; no new safety signals.
Companies Mentioned
- argenx SE (ARGX): Central data release at EULAR; topline Phase 3 results due 3Q2026; potential widening of FcRn program.
- Halozyme Therapeutics (HALO): ENHANZE delivery enables SC efgartigimod; potential impact on administration and uptake.
Industry News
Category: Industry News. The press release summarizes multiple clinical data readouts and upcoming catalysts, underscoring ARGX's FcRn strategy and potential expansion across autoimmune rheumatic diseases.